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AbstrACt
Objective Smoking in people with serious mental illness 
is a major public health problem and contributes to 
significant levels of morbidity and mortality. The aim of 
the review was to systematically examine the efficacy of 
methods used to aid smoking cessation in people with 
serious mental illness.
Method A systematic review and meta-analysis of 
randomised controlled trials to compare the effectiveness 
and safety of pharmacological and behavioural 
programmes for smoking cessation in people with serious 
mental illness. Electronic databases were searched for 
trials to July 2018. We used the Cochrane Collaboration’s 
tool for assessing the risk of bias.
results Twenty-eight randomised controlled trials were 
identified. Varenicline increased the likelihood of smoking 
cessation at both 3 months (risk ratio (RR) 3.56, 95% CI 
1.82 to 6.96, p=0.0002) and at 6 months (RR 3.69, 
95% CI 1.08 to 12.60, p=0.04). Bupropion was effective 
at 3 months (RR 3.96, 95% CI 1.86 to 8.40, p=0.0003), 
especially at a dose of 300 mg/day, but there was no 
evidence of effect at 6 months (RR 2.22, 95% CI 0.52 to 
9.47, p=0.28). In one small study, nicotine therapy proved 
effective at increasing smoking cessation up to a period 
of 3 months. Bupropion used in conjunction with nicotine 
replacement therapy showed more effect than single 
use. Behavioural and bespoke interventions showed little 
overall benefit. Side effects were found to be low.
Conclusion The new information of this review was the 
effectiveness of varenicline for smoking cessation at both 
3 and 6 months and the lack of evidence to support the 
use of both bupropion and nicotine products for sustained 
abstinence longer than 3 months. Overall, the review found 
relatively few studies in this population.
IntrOduCtIOn
Smoking in people with serious mental 
illness continues to be a major public health 
problem with levels of smoking remaining 
as high as 70%,1–3 compared with about 
20% in the general population.4 Smoking 
contributes to the high levels of morbidity 
and mortality in this population5 with 
mortality rates continuing to remain around 
twice those found in the general population, 
with high levels of cardiovascular and respi-
ratory disease.1 6 7 Individuals with serious 
mental illness tend to have smoked for 
longer periods compared with other groups 
and are commonly classed as heavy smokers, 
smoking >25 cigarettes per day.8 They often 
start before the onset of their illness, are 
younger than non-smokers and most of them 
are male.9 Generally, they prefer cigarettes 
high in nicotine and more frequently smoke 
cigarettes down to the very end.10 Increased 
nicotine intake per cigarette is associated 
with more intense cigarette puffing contrib-
uting to the higher serum nicotine levels, 
approximately 1.3 times those in non-men-
tally ill controls.11 12 The effect of this greater 
uptake of nicotine may lead to higher than 
expected levels of nicotine dependence and 
strengths and limitations of this study
 ► This study systematically reviewed all pharmacolog-
ical and behavioural interventions to promote smok-
ing cessation in people with serious mental illness.
 ► We used the Grading of Recommendations 
Assessment, Development and Evaluation approach 
to evaluate the strength and quality of the evidence.
 ► We reviewed and identified evidence that would be 
valuable and relevant to clinical practice.
 ► Research in this field was limited by a small number 
and low quality of randomised controlled trials.
 ► We recommended that studies with larger sample 
sizes are needed particularly to compare the relative 
effects of one smoking treatment versus another.
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withdrawal symptoms, even with moderate amounts of 
smoking.11 
There is therefore an urgent need to develop and eval-
uate smoking cessation interventions that work in clinical 
settings for people with severe mental illness who are 
about as likely as the general population to want to quit 
smoking.13 However, so far the primary focus of existing 
smoking cessation programmes in this population has 
been based on the use of nicotine replacement products. 
There is a reluctance among some clinicians to consider 
new treatments that may be more effective. This may be 
due to lack of clarity on the effectiveness of these prod-
ucts or concern about side effects.14 Early reports using 
medication such as varenicline had raised concerns as to 
its effect on the mental health of individuals.15
The aim of this new review was to compare the effec-
tiveness and safety of existing pharmacological and 
behavioural programmes for smoking cessation in people 
with serious mental illness. Clinicians need clear informa-
tion to be able to compare the relative benefits and poten-
tial side effects of these treatments for their patients.
MethOds
Criteria for considering studies for this review.
types of studies
All randomised controlled trials.
types of participants
Adults with schizophrenia or other types of schizophre-
nia-like psychosis, schizoaffective disorders and bipolar 
affective disorder, irrespective of the diagnostic criteria 
used, age, ethnicity and sex.
types of interventions
We only included interventions where the primary aim of 
the study was to achieve smoking cessation.
types of outcome measures
We used the strictest definition of abstinence, that is, 
preferring sustained over point prevalence abstinence 
and using biochemically validated rates where available. 
However, if this was not available the best alternative 
would be used. When both outcomes were available, we 
considered sustained abstinence to be a superior clinical 
marker of abstinence. Secondary outcome measures were 
changes in safety (adverse effects), mental state, general 
functioning and cognitive functioning.
search methods and study selection
We searched the following electronic databases: Ovid 
MEDLINE, Embase, CINAHL, PsycINFO, Biological 
Abstracts on Ovid and The Cochrane Library (start 
January 2017, last search July 2018). The systematic search 
(online supplementary appendix A) included hand 
searching of journals, books, cross-referencing and bulle-
tins (eg, brief reports/brief statement of facts). The search 
filter, the Cochrane Highly Sensitive Search Strategy, was 
used to assist in the identification of randomised trials in 
MEDLINE.16 No articles were excluded on the basis of 
language during the search.
The abstracts of studies were examined by RP. Full text 
of the studies that potentially met the eligibility criteria 
was obtained. Selection of studies was conducted by RP 
and any discrepancies or difficulties were discussed with 
co-investigators (JG and DJS). Articles were checked 
for duplication of the same data. Smoking cessation 
was measured at 3, 6 and 12 months if possible, or the 
closest available data to that time point. Side effects were 
measured at the available data end points at 3, 6 and 
12 months, if possible.
data extraction and analysis
Data were extracted by one author (RP) and checked for 
accuracy by the second (DJS). Data were extracted onto 
prepared forms to include: participants and setting, loca-
tion, description of the intervention, study size, method-
ological issues, risk of bias, results and general comments. 
All analyses were conducted using RevMan Manager V.5.3. 
We performed a Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses evaluation of our meta-anal-
ysis using a standard checklist of 27 items that ensure the 
quality of a systematic review or meta-analysis.17
Data from intention to treat analyses were used when 
available or endpoint data for participants who completed 
the programme. For dichotomous outcomes, the fixed 
effects risk ratio (RR) and its 95% CI were calculated 
using the Mantel-Haenszel method.18 If heterogeneity 
was found, a random effects model was used. For contin-
uous data, the standardised mean difference (SMD) with 
95% confidence intervals was calculated as the difference 
in means between groups divided by the pooled SD. If no 
SD were found they were calculated from standard errors, 
confidence intervals, or t values.19 Authors were contacted 
for missing data if analyses could not be completed. Statis-
tical heterogeneity was investigated using two methods: 
Figure 1 Flow chart of the results of the systematic 
search. NRT, nicotine replacement therapy.
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visual inspection of the forest plots and the I2 test. The 
degree of heterogeneity was categorised as follows: 0% to 
40% low level of heterogeneity; 30% to 60% moderate 
heterogeneity; 50% to 90% substantial heterogeneity; 
75% to 100%: considerable heterogeneity.19
Sensitivity analyses were conducted to determine the 
effect of dosage of medication used, and whether chem-
ical confirmation of smoking cessation affected treatment 
outcomes. It was planned to use funnel plots to assess 
publication bias graphically and Begg and Egger tests to 
assess the risk of bias statistically.19 20 We performed sensi-
tivity analyses to explore the influence of each risk of bias 
domain on pooled treatment effects where the risk was 
high.
The safety outcomes extracted from included trials 
were the number of patients reporting any adverse event, 
the number of patients reporting any serious adverse 
event, and number of patients withdrawn from the 
study because of adverse events. We contacted authors 
to provide further information when there were insuffi-
cient data reported in the paper. Data were pooled for the 
identified adverse events.
Quality assessment
We used the Cochrane Collaboration’s tool for assessing 
the risk of bias.19 The following recommended domains 
were considered: sequence generation, allocation 
concealment, blinding, incomplete outcome data, selec-
tive outcome reporting and other sources of bias. Each 
item was rated according to the level of bias and catego-
rised into either low, high or unclear. The category unclear 
indicated unclear or unknown risk of bias.19 RevMan 
V.5.3.5 was used to generate figures and summaries.
The quality of evidence was rated for each pooled 
analysis with the Grading of Recommendations Assess-
ment, Development and Evaluation (GRADE) system.19 
Outcomes of interest were ranked according to their rele-
vance for clinical decision.
Patient and public involvement statement
No patients or public representatives were involved in the 
completion of this review.
results
The electronic search identified 1377 potentially eligible 
reports. Eight hundred and fifty-two were excluded on 
the basis of the title or abstract alone. We retrieved the 
full text of 202 articles and excluded a further 174 studies 
(figure 1, online supplementary appendix B). Additional 
papers were found from searching, cross-referencing and 
bulletins.
All included studies had been published between 
2000 and 2016. A total of 28 studies were identified. 
The studies varied in their setting, size, age and type of 
intervention (table 1). Only five studies examined indi-
viduals with bipolar affective disorder.21–25 Of these, two 
studies were of varenicline, one of bupropion and two S
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using behavioural techniques in both schizophrenia 
and bipolar disorder. We found eight studies comparing 
bupropion versus placebo (table 1).
Six studies used 300 mg of bupropion per day and two 
used bupropion 150 mg/day. Seven studies examined the 
effect of varenicline versus placebo, and one study nico-
tine replacement therapy (NRT) versus placebo (table 1).
Outcomes
The main outcome measure was smoking abstinence at 3 
and 6 months. Twelve-month follow-up was found in four 
studies (table 1). Five studies did not confirm smoking 
abstinence using chemical markers (table 1).
Meta-analyses
Bupropion
Six out of eight studies provided data to combine the 
effects of bupropion versus placebo (table 2). The 
pooled risk ratio (RR) of bupropion (150 and 300 mg/
day) at 3 months for smoking abstinence favoured bupro-
pion against placebo (n=6, n=235, RR 3.96, 95% CI 
1.86 to 8.40, p=0.0003; heterogeneity: Χ²=1.64, df=5, 
p=0.90; I²=0%) (figure 2).
Pooled results at 6 months of bupropion versus 
placebo showed no effect (n=3, n=104, RR 2.22, 95% CI 
0.52 to 9.47, p=0.28; heterogeneity: χ2=0.34, df=2, p=0.85; 
I2=0%) (figure 3). The pooled RR showed a greater likeli-
hood of smoking cessation using a dose of 300 mg/day of 
bupropion at 3 months (dose 150 mg: n=2, n=65, RR 2.01, 
95% CI 0.49 to 8.28, p=0.33; dose 300 mg: n=4, n=170, RR 
4.99, 95% CI 2.01 to 12.39, p=0.0005). No effect was found 
using doses of 150 or 300 mg/day at 6 months (dose 
150 mg: n=1, n=19, RR 2.73, 95% CI 0.12 to 59.57, p=0.52; 
dose 300 mg: n=2, n=85, RR 2.09, 95% CI 0.40 to 10.80, 
p=0.38).
Bupropion was effective for smoking cessation in indi-
viduals with a diagnosis of schizophrenia at 3 months 
(n=5, n=230, RR 3.95, 95% CI 1.81 to 8.62, p=0.0006). 
No effect was found in bipolar disorders in one small 
study (n=1, n=5, RR 4.00, 95% CI 0.24 to 67.71, p=0.34) 
(table 2).
Table 2 Meta-analysis comparison: risk ratio of smoking cessation at 3 months
Outcome or subgroup title
No. of studies
(available data) No. of participants Risk ratio (95% CI) P value
Total meta-analysis
  Bupropion 6 n=235 3.96 (1.86 to 8.40) 0.0003
  Varenicline 4 n=288 3.56 (1.82 to 6.96) 0.0002
  NRT 1 n=298 2.74 (1.10 to 6.81) 0.03
  Bupropion+NRT 2 n=110 2.39 (1.14 to 5.00) 0.02
  NRT/Behavioural counselling 1 n=45 0.99 (0.44 to 2.23) 0.98
  High/Low NRT 1 n=184 0.25 (0.03 to 2.19) 0.21
Schizophrenia
  Bupropion 5 n=230 3.95 (1.81 to 8.62) 0.0006
  Varenicline 3 n=228 3.06 (1.32 to 7.10) 0.009
Bipolar disorder
  Bupropion 1 n=5 4.00 (0.24 to 67.71) 0.34
  Varenicline 1 n=60 4.68 (1.68 to 14.50) 0.008
NRT, nicotine replacement therapy. 
Figure 2 Pooled effect of bupropion vs placebo for smoking cessation at 3 months.
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Varenicline
Four out of seven studies provided data comparing the 
effect of varenicline with placebo. The pooled RR at 
3 months for smoking abstinence favoured varencline 
(n=4, n=288, RR 3.56, 95% CI 1.82 to 6.96, p=0.0002; 
heterogeneity: Χ²=1.99, df=3, p=0.57; I2=0%) (figure 4). 
Pooled analysis at 6 months also favoured varenicline (n=2, 
n=188, RR 3.69, 95% CI 1.08 to 12.60, p=0.04; heteroge-
neity: χ2=0.22, df=1, p=0.64; I2=0%) (figure 5). Vareni-
cline was effective for smoking cessation at 3 months in 
both schizophrenia and bipolar disorder (table 2) (RR 
3.06 vs 4.68). However at 6 months no effect was found in 
either disorder.
nicotine replacement therapy
Baker et al26 compared NRT versus placebo at 3, 6 and 12 
months (figure 6). The RR favoured NRT at 3 months 
(n=1, n=298, RR 2.74, 95% CI 1.10 to 6.81, p=0.03), but 
not at 6 months (n=298, RR 2.74, 95% CI 0.74 to 10.12, 
p=0.13) or 12 months (n=298, RR 5.14, 95% CI 
0.61 to 43.44, p=0.13). Chen et al27 compared high-dose 
versus low-dose NRT, but found no difference in effect at 
3 months (n=184, RR 0.25, 95% CI 0.03 to 2.19, p=0.21).
Combinations of treatment included in the meta-analyses
Several studies used combinations of treatments for 
smoking cessation. Data from two studies were combined 
comparing the effects of bupropion and NRT therapy 
versus placebo, at 3 and 6 months.28 29 The pooled RR 
favoured the combination of treatments at 3 months 
(n=2, n=110, RR 2.88, 95% CI 1.23 to 6.73, p=0.01; 
heterogeneity: Χ²=1.72, df=1, p=0.19; I²=42%) and at 
6 months (n=2, n=110, RR 3.86, 95% CI 1.01 to 14.80, 
p=0.05; heterogeneity: Χ²=0.56, df=1, p=0.46, I²=0%). Of 
these studies, Evins et al28 found no effect (n=51, RR 2.60, 
95% CI 0.55 to 12.19, p=0.23).
However, data from all studies of bupropion using 
bupropion treatment alone and two studies combining 
bupropion and NRT versus placebo were favourable 
at 3 months (n=8, n=345, RR 3.48, 95% CI 1.98 to 6.11, 
p=0.0001; heterogeneity: Χ²=3.77, df=7, p=0.81, I²=0%) 
and 6 months (n=5, n=214, RR 3.04, 95% CI 1.14 to 8.09, 
p=0.03; heterogeneity: Χ²=1.08, df=4, p=0.90, I²=0%) 
(figure 7).
behavioural and bespoke programmes
No meta-analysis was used due to the heterogeneity of 
both intervention and comparison groups (online supple-
mentary appendix C, Table 1). Two studies compared the 
effect of NRT with different types of behavioural coun-
selling.30 31 George et al31 found no effect at 3 months 
(n=45, RR 1.01, 95% CI 0.45 to 2.28, p=0.98) or 6 months 
(n=45, RR 0.61, 95% CI 0.14 to 2.67, p=0.51). Williams et 
al30 compared two behavioural counselling approaches, 
high-intensity (TANS: Treatment of Addiction to Nico-
tine in Schizophrenia) versus a low-intensity behavioural 
counselling programme (MM: Medication Management). 
Figure 3 Pooled effect of bupropion vs placebo for smoking cessation at 6 months.
Figure 4 Pooled effect of varenicline vs placebo for smoking cessation at 3 months.
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No difference in levels of smoking cessation was found 
in both groups at 3 months (15.6% TANS vs. 26.2% MM, 
p=0.221).
Bennett et al24 compared a multifaceted behavioural 
group intervention versus a supportive group interven-
tion and found no difference in effect at 3 months (n=95, 
RR 1.13, 95% CI 0.37 to 3.44, p=0.83). Some individuals 
used medication to support smoking cessation such as 
bupropion or NRT.
Gilbody et al25 offered a bespoke smoking cessa-
tion (BSC) programme (SCIMITAR) to individuals 
with serious mental illness compared with usual care. 
Pharmacotherapies were prescribed by the individual’s 
general practitioner (GP) to aid smoking cessation (BSC 
group: nicotine=77, bupropion=0, varenicline=0, e-ciga-
rette=3, either separately or in combination, as decided 
by the GP). During the trial period 48% of individuals 
in the intervention group received pharmacotherapies 
compared with 19% of the placebo group. The odds of 
quitting at 12 months was higher in the BSC intervention 
(36% vs 23%) but did not reach statistical significance 
(OR 2.94, 95% CI 0.8 to 10.5, p=0.1).
sensitivity analyses
Sensitivity analyses found that bupropion at a dose of 
300 mg/day increased the likelihood of smoking cessation 
at 3 months (dose 150 mg: n=2, n=65, RR 2.01, 95% CI 
0.49 to 8.28, p=0.33; dose 300 mg: n=4, n=170, RR 4.99, 
95% CI 2.01 to 12.39, p=0.0005). Studies that did not 
use chemical markers to confirm smoking cessation did 
not substantially affect the likelihood of cessation with 
bupropion (n=5, n=155, RR 3.93, 95% CI 1.48 to 10.40, 
p=0.006). Chemical verification of smoking cessation was 
used in all studies of varenicline and NRT included in the 
meta-analysis in this review.
Clinical effectiveness and numbers needed to treat
The number needed to treat (NNT) for the cessation of 
smoking using varenicline at 3 months was six patients 
(risk difference (RD) 0.19, 95% CI 0.11 to 0.27) (table 3), 
and 10 patients at 6 months (RD 0.1, 95% CI 0.03 to 0.18). 
Varenicline resulted in 24.8% of the patients in the inter-
vention group vs 7.3% patients in the placebo group 
being abstinent from smoking at 3 months (at 6 months 
this was 13.8% vs 4.2%, respectively).
The NNT for the cessation of smoking using bupro-
pion at 3 months was six patients (RD 0.19, 95% CI 0.10 
to 0.28) (table 3). NRT was the least effective, requiring 
15 patients to receive treatment at 3 months (RD 0.07, 
95% CI 0.01 to 0.13). Combinations proved to be the 
least effective of treatments to aid cessation of smoking 
(table 3).
side effects
Side effects from medication were reviewed systemat-
ically to allow pooling of data where possible (table 4). 
Pooled analysis found that bupropion did not affect posi-
tive and negative symptoms or depressive and anxiety 
symptoms. Serious adverse events in individual patients 
were noted with bupropion. Evins et al32 found that one 
participant, who was randomised to bupropion, experi-
enced hives, urticaria and wheezing in the first week on 
Figure 5 Pooled effect of varenicline vs placebo for smoking cessation at 6 months.
Figure 6 Pooled effect of nicotine replacement therapy vs placebo for smoking cessation at 3 months.
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study medication, consistent with an allergic reaction 
to bupropion. Weiner et al33 found that one participant 
developed a rash that resolved after medication discon-
tinued. Another patient suffered a seizure and was found 
to be hyponatraemic.
Pooled analysis showed a low level of side effects with 
varenicline (table 4). The main finding was that vareni-
cline led to problems with nausea and vomiting, but had 
no other effects on depressive symptoms, anxiety symp-
toms or suicidal ideation. Serious adverse events were 
noted with varenicline in individual patients. Williams et 
al34 found that five patients in the treatment group and 
three patients in the placebo group experienced suicidal 
thoughts. However, the authors found no clear pattern 
between suicidal thoughts and medication assignment. 
One patient with depression and suicidal thoughts took 
an overdose of medication, while another participant 
took an overdose and had a seizure. Wu et al22 found 
that one patient experienced suicidal ideation but this 
was reported to be associated with additional situational 
stressors rather than a medication effect.
No notable side effects were described for programmes 
using NRT (table 4).
Quality assessment
We found a total of 28 studies which varied in their meth-
odological quality, including the method of sequence 
generation during randomisation, sequence alloca-
tion concealment, blinding of participants, outcome 
assessment and incomplete analysis of outcome data 
(online supplementary appendix D, Table 1). Ten 
studies23 26–28 33 35–39 described using intention-to-treat 
analysis for data analysis. Participants failing to complete 
these studies were included as non-abstinent smokers in 
their analysis. Only three studies23 29 35 described a sample 
size calculation. The interpretation of funnel plots 
(figure 8) was limited due to the small number of pooled 
results in this analysis, and similarly Egger tests were not 
preformed due to the low number of available studies.
We used the Cochrane Collaboration’s tool19 for 
assessing the risk of bias (figure 9). This showed that most 
studies described used inadequate methods of sequence 
generation during randomisation, blinding of partici-
pants, analysis of outcome data, poorer methods of allo-
cation concealment and blinding of outcome assessment. 
We found that Smith et al40 showed the lowest risk of bias 
in all domains.
The quality of evidence was rated for each pooled anal-
ysis with the GRADE assessment of study quality. The 
GRADE clinical evidence profile graded the studies of 
bupropion (at 3 or 6 months) and varenicline as being of 
very low quality (online supplementary file 4, Tables 2–3).
dIsCussIOn
In this review, we compare up-to-date findings of 
programmes used to aid the cessation of smoking for 
Figure 7 Pooled effect of bupropion only and combined bupropion/nicotine replacement therapy studies vs placebo for 
smoking cessation at 6 months.
Table 3 Risk difference (RD) and number  needed to treat (NNT) of smoking cessation at 3 months
Outcome or 
subgroup title No. of studies No. of participants RD NNT P value
Bupropion 6 235 0.19 (0.10 to 0.28) 6 <0.0001
Varenicline 4 288 0.19 (0.11 to 0.27) 6 <0.00001
NRT 1 298 0.07 (0.01 to 0.13) 15 0.02
Bupropion+NRT 2 110 0.20 (0.05 to 0.36) 5 0.006
NRT/Behavioural 
counselling
1 45 0.00 (−0.28 to 0.29) – 0.98
High/Low NRT 1 184 −0.03 (−0.08 to 0.01) 34 0.17
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people with serious mental illness, with outcomes at 3, 6 
and 12 months. The primary new information of this review 
was the effectiveness of varenicline at 3 and 6 months but 
the lack of evidence to support the use of bupropion 
and nicotine products to achieve smoking cessation for 
>3 months. We also found that these treatments did not 
notably affect the physical or mental health of the partici-
pants, with generally low levels of side effects. Varenicline 
was the most successful treatment with individuals more 
than three times as likely to achieve smoking cessation 
in both schizophrenia and bipolar disorders. Problems 
with side effects from nausea and vomiting were found 
with varenicline. Bupropion increased the cessation of 
smoking in the short term (up to 3 months) compared 
with placebo, at a dose of 300 mg/day, but there was a 
lack of evidence to support its use in achieving sustained 
cessation of smoking over a longer period. Only one small 
study was found that used NRT and this was only effective 
for a period of up 3 months. We found that combining 
bupropion and NRT was only effective at 3 months. 
However, when all studies of bupropion were pooled at 
6 months, both single treatments using bupropion and 
those using concurrent bupropion and nicotine, stronger 
evidence was observed. Behavioural interventions on the 
whole showed little benefit to achieve smoking cessa-
tion. Counselling and behavioural or specialised bespoke 
programmes used different types of interventions to 
achieve smoking cessation but no consistent effect was 
found. Contingency reinforcement combined with NRT 
was found to be beneficial for achieving smoking cessa-
tion compared with contingency reinforcement alone. 
Comparison of the effect of behavioural or contingency 
programmes versus pharmacological interventions could 
not be made due to the heterogeneity of the active and 
comparison groups used.
There are strengths and limitations to the findings we 
have presented. We found that effective methods are 
available to increase rates of smoking cessation both in 
schizophrenia and bipolar affective disorder. However, 
this evidence is based on relatively few studies. We iden-
tified all randomised trials including results available at 
both 3 and 6 months, and identified studies that used 
Table 4 Smoking cessation side effects of treatment
Outcome or subgroup title No. of studies No. of participants Statistical result P value
Bupropion
  Positive 2 n=85 SMD −0.24 (−0.66 to −0.19) 0.28 
  Negative 2 n=85 SMD −0.15 (−0.58 to −0.27) 0.48
  Depressive 2 n=85 SMD −0.17 (−0.59 to −0.26) 0.44
  Anxiety 1 n=53 SMD 0.18 (−0.36 to −0.72) 0.52
Varenicline
  Headache 3 n=188 RR 0.71 (0.45 to 1.13) 0.15
  Sleep problem 4 n=288 RR 1.25 (0.77 to 2.03) 0.37
  Nausea/Vomiting 4 n=288 RR 1.66 (1.23 to 2.24) 0.0009
  Diarrhoea 2 n=188 RR 1.15 (0.38 to −3.49) 0.80
  Depression 2 n=188 RR 1.72 (0.67 to −4.45) 0.26
  Anxiety 2 n=188 RR 0.88 (0.29 to −2.66) 0.82
  Suicidal ideation 2 n=188 RR 1.05 (0.33 to 3.41) 0.93
Nicotine replacement therapy
  Depressive 1 n=246 SMD −0.13 (−0.38 to −0.12) 0.31
  Anxiety 1 n=212 SMD −0.05 (−0.32 to −0.22) 0.72
RR, risk ratio; SMD, standardised mean difference. 
Figure 8 Funnel plots of smoking cessation studies. (A)
Funnel plot of comparison: bupropion 3 months. (B) Funnel 
plot of comparison: bupropion 6 months. (C) Funnel plot 
of comparison: varenicline 3 months. (D) Funnel plot of 
comparison: varenicline 6 months. RR, risk ratio. 
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chemical markers to confirm smoking abstinence. A 
number of limitations however need to be acknowledged. 
Research in this field has been so far limited by only a 
small number and low quality of randomised controlled 
trials. For example, some of the conclusions from this 
review are based on a single study of NRT. It is possible 
that additional studies with negative outcomes have been 
conducted but remain unpublished. We found generally 
low levels of side effects with both bupropion use and 
varenicline. However, we are aware that studies comprising 
larger samples are still required to fully resolve issues of 
whether there are a greater potential risk of suicidality 
and other neuropsychiatric effects with these products 
used for smoking cessation.
Our findings update and review the latest evidence in 
this field and show that successful treatment for smoking 
dependence is available in people with serious mental 
illness. However, our conclusions differ in respect of the 
final analysis of treatments using bupropion therapy. 
For example, Tsoi et al41 in a Cochrane systematic review 
of patients with schizophrenia (last search November 
2012) found that bupropion was effective at both 3 and 
6 months. Their final conclusions differed from our own 
in their summary of findings of bupropion reported at 
6 months. Their final analysis of bupropion studies at 
6 months incorporated both studies where bupropion 
was used singly as the primary treatment offered and also 
those using concurrent treatments of bupropion and 
nicotine therapy. The pooled effect of the larger sample 
size found stronger evidence to support the use of bupro-
pion at 6 months treatment. A recent systematic review 
by Peckham et al42  similarly incorporated into their find-
ings of bupropion studies that jointly used bupropion 
and NRT. In our review, we have reported the outcomes 
of bupropion separately as, first, we did not think it 
likely that clinicians would incorporate two concurrent 
treatments for smoking cessation, and second, existing 
meta-analysis of studies in the general population have 
tended to compare one product for smoking cessation 
solely with another.43
The results of our review are tempered by the relatively 
low numbers of randomised trials in this field, most trials 
being underpowered, and the poor quality of evidence 
identified by the GRADE assessment. For example, only 
two studies showed the effectiveness of varenicline at 6 
months, and only one study44 was found examining nico-
tine products, compared with up to 70 studies comparing 
NRT in the general population. We found low levels of 
side effects, with varenicline mainly causing symptoms of 
nausea and vomiting. We are aware that a larger study has 
been recently completed45 examining the neuropsychi-
atric effects of varenicline, bupropion and NRT in indi-
viduals with or without psychiatric disorders (n=4074), 
comprising unipolar and bipolar disorders, anxiety 
disorders, personality disorders and psychotic illness. 
This study did not find a greater risk of neuropsychiatric 
side effects associated with these medications. Data were 
not available (authors contacted) for inclusion in this 
review and meta-analysis.
Implications for practice
This is a new and updated systematic review directly 
comparing treatments to aid cessation of smoking in 
people with schizophrenia and bipolar affective disor-
ders. We found that smoking cessation was more likely to 
be successful using varenicline in both schizophrenia and 
bipolar disorders with few side effects but there was a lack 
of sufficient evidence to support the use of bupropion as 
a single treatment in the medium and long term. Treat-
ment with varenicline resulted in 24.8% of the patients at 
3 months in the varenicline group vs 7.3% in the placebo 
group being abstinent from smoking (at 6 months, 13.8% 
vs 4.2%, respectively). However, our review is notable by 
the low number of studies available for each smoking 
cessation treatment.
Implications for research
Further research is needed to conduct well-designed 
studies of adequate sample size to determine the most 
effective method for reducing smoking in this population. 
Figure 9 Risk of bias graph: review authors’ judgements about each risk of bias item presented as percentages across all 
included studies.
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Studies so far have also achieved only relatively short-
term effects on sustained smoking abstinence. Tailored 
or focused programmes may be needed using single or 
combinations of treatments to achieve better outcomes. 
Similarly, clearer evidence is required to understand 
which type of counselling or psychological intervention 
is the most effective. Furthermore, existing smoking 
cessation programmes tend to rely on evidence from 
general population samples. It is not clear whether these 
are transferable to people with serious mental illnesses 
with substantially higher levels of smoking and nicotine 
dependence. However, we also need to be realistic as to 
the problems of change in this population who as a result 
of the nature of their mental illness may be less motivated 
or less able to change their lifestyle.46 47
COnClusIOns
This review highlighted the paucity of studies found to 
address the high prevalence of smoking in people with SMI 
and identifies a need for further randomised controlled 
trials. The available evidence suggested that varenicline 
was the most effective with low levels of side effects, but 
there was a lack of sufficient evidence to support the use 
of bupropion and NRT within this group.
Contributors RP, DJS and JRG developed the research. RP conducted the 
research. RP and DJS conducted the analysis. RP drafted the manuscript. DJS and 
JRG provided input and approved the final version.
Funding The authors have not declared a specific grant for this research from any 
funding agency in the public, commercial or not-for-profit sectors. 
Competing interests RP and DJS declared no competing interests. JG has 
received research funding from MRC, ESRC, NIHR, Stanley Medical Research 
Institute and has received donations of drugs supplies for trials from Sanofi-Aventis 
and GSK. He has acted as an expert witness for Dr Reddys. 
Patient consent for publication Not required.
Provenance and peer review Not commissioned; externally peer reviewed.
data sharing statement No other unpublished data are available for this study.
Open access This is an open access article distributed in accordance with the 
Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non-commercially, 
and license their derivative works on different terms, provided the original work is 
properly cited, appropriate credit is given, any changes made indicated, and the use 
is non-commercial. See: http:// creativecommons. org/ licenses/ by- nc/ 4. 0/.
OrCId id
Daniel J Smith http:// orcid. org/ 0000- 0002- 2267- 1951
reFerenCes
 1 Goff DC, Sullivan LM, McEvoy JP, et al. A comparison of ten-year 
cardiac risk estimates in schizophrenia patients from the CATIE study 
and matched controls. Schizophr Res 2005;80:45–53.
 2 McCreadie RG. Scottish Schizophrenia Lifestyle Group. Diet, 
smoking and cardiovascular risk in people with schizophrenia: 
descriptive study. Br J Psychiatry 2003;183:534–9.
 3 Susce MT, Villanueva N, Diaz FJ, et al. Obesity and associated 
complications in patients with severe mental illnesses: a cross-
sectional survey. J Clin Psychiatry 2005;66:167–73.
 4 Scottish Health Survey 2. The Scottish Government, Edinburgh, 
2010. www.  scotland. gov. uk/ publications.
 5 Kelly DL, McMahon RP, Wehring HJ, et al. Cigarette smoking 
and mortality risk in people with schizophrenia. Schizophr Bull 
2011;37:832–8.
 6 Saha S, Chant D, McGrath J. A systematic review of mortality in 
schizophrenia: is the differential mortality gap worsening over time? 
Arch Gen Psychiatry 2007;64:1123–31.
 7 Leucht S, Burkard T, Henderson J, et al. Physical illness and 
schizophrenia: a review of the literature. Acta Psychiatr Scand 
2007;116:317–33.
 8 de Leon J, Diaz FJ. A meta-analysis of worldwide studies 
demonstrates an association between schizophrenia and tobacco 
smoking behaviors. Schizophr Res 2005;76:135–57.
 9 Kelly C, McCreadie RG. Smoking habits, current symptoms, and 
premorbid characteristics of schizophrenic patients in Nithsdale, 
Scotland. Am J Psychiatry 1999;156:1751–7.
 10 Lohr JB, Flynn K. Smoking and schizophrenia. Schizophr Res 
1992;8:93–102.
 11 Williams JM, Ziedonis DM, Abanyie F, et al. Increased nicotine and 
cotinine levels in smokers with schizophrenia and schizoaffective 
disorder is not a metabolic effect. Schizophr Res 2005;79:323–35.
 12 Strand JE, Nybäck H. Tobacco use in schizophrenia: a study of 
cotinine concentrations in the saliva of patients and controls. Eur 
Psychiatry 2005:20:50–4.
 13 Hall SM, Prochaska JJ. Treatment of smokers with co-occurring 
disorders: emphasis on integration in mental health and addiction 
treatment settings. Annu Rev Clin Psychol 2009;5:409–31.
 14 Cerimele JM, Durango A. Does varenicline worsen psychiatric 
symptoms in patients with schizophrenia or schizoaffective disorder? 
J Clin Psychiatry 2012;73:e1039–e1047.
 15 US Food and Drug Administration. FDA Alert. Information for 
Healthcare Professionals: Varenicline (marketed as Chantix) and 
Bupropion (marketed as Zyban, Wellbutrin, and generics). 2009. 
US Food and Drug Administration http://www. fda. gov/ downloads/ 
AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/
 16 Dickersin K, Scherer R, Lefebvre C. Identifying relevant studies for 
systematic reviews. Br Med J 1994;309:1286.
 17 Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for 
systematic reviews and meta-analyses: the PRISMA statement. PLoS 
Med 2009;6:e1000097.
 18 Mantel N, Haenszel W. Statistical aspects of the analysis of data from 
retrospective studies of disease. J Natl Cancer Inst 1959;22:719–48.
 19 Higgins JPT, Green S. Cochrane handbook for systematic reviews of 
interventions. England: Wiley-Blackwell, 2008.
 20 Egger M, Smith GD, Altman DG. Systematic reviews in health care - 
meta-analysis in context 2e: John Wiley & Sons.
 21 Weinberger AH, Vessicchio JC, Sacco KA, et al. A preliminary study 
of sustained-release bupropion for smoking cessation in bipolar 
disorder. J Clin Psychopharmacol 2008;28:584–7.
 22 Wu BS, Weinberger AH, Mancuso E, et al. A preliminary feasibility 
study of varenicline for smoking cessation in bipolar disorder. J Dual 
Diagn 2012;8:131–2.
 23 Chengappa KN, Perkins KA, Brar JS, et al. Varenicline for smoking 
cessation in bipolar disorder: a randomized, double-blind, placebo-
controlled study. J Clin Psychiatry 2014;75:765–72.
 24 Bennett ME, Brown CH, Li L, et al. Smoking cessation in individuals 
with serious mental illness: a randomized controlled trial of two 
psychosocial interventions. J Dual Diagn 2015;11:161–73.
 25 Gilbody S, Peckham E, Man MS, et al. Bespoke smoking cessation 
for people with severe mental ill health (SCIMITAR): a pilot 
randomised controlled trial. Lancet Psychiatry 2015;2:395–402.
 26 Baker A, Richmond R, Haile M, et al. A randomized controlled trial 
of a smoking cessation intervention among people with a psychotic 
disorder. Am J Psychiatry 2006;163:1934–42.
 27 Chen HK, Lan TH, Wu BJ. A double-blind randomized clinical trial of 
different doses of transdermal nicotine patch for smoking reduction 
and cessation in long-term hospitalized schizophrenic patients. Eur 
Arch Psychiatry Clin Neurosci 2013;263:75–82.
 28 George TP, Vessicchio JC, Sacco KA, et al. A placebo-controlled trial 
of bupropion combined with nicotine patch for smoking cessation in 
schizophrenia. Biol Psychiatry 2008;63:1092–6.
 29 Evins AE, Cather C, Culhane MA, et al. A 12-week double-blind, 
placebo-controlled study of bupropion sr added to high-dose dual 
nicotine replacement therapy for smoking cessation or reduction in 
schizophrenia. J Clin Psychopharmacol 2007;27:380–6.
 30 Williams JM, Steinberg ML, Zimmermann MH, et al. Comparison of 
two intensities of tobacco dependence counseling in schizophrenia 
and schizoaffective disorder. J Subst Abuse Treat 2010;38:384–93.
 31 George TP, Ziedonis DM, Feingold A, et al. Nicotine transdermal 
patch and atypical antipsychotic medications for smoking cessation 
in schizophrenia. Am J Psychiatry 2000:157:1835–42.
 32 Evins AE, Cather C, Deckersbach T, et al. A double-blind 
placebo-controlled trial of bupropion sustained-release for 
smoking cessation in schizophrenia. J Clin Psychopharmacol 
2005;25:218–25.
copyright.
 o
n
 D
ecem
ber 3, 2019 at University of G
lasgow. Protected by
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-027389 on 28 November 2019. Downloaded from 
12 Pearsall R, et al. BMJ Open 2019;9:e027389. doi:10.1136/bmjopen-2018-027389
Open access 
 33 Weiner E, Ball MP, Buchholz AS, et al. Bupropion sustained release 
added to group support for smoking cessation in schizophrenia: 
a new randomized trial and a meta-analysis. J Clin Psychiatry 
2012;73:95–102.
 34 Williams JM, Gandhi KK, Lu SE, et al. Nicotine intake and smoking 
topography in smokers with bipolar disorder. Bipolar Disord 
2012;14:618–27.
 35 Williams JM, Anthenelli RM, Morris CD, et al. A randomized, double-
blind, placebo-controlled study evaluating the safety and efficacy of 
varenicline for smoking cessation in patients with schizophrenia or 
schizoaffective disorder. J Clin Psychiatry 2012;73:654–60.
 36 Gallagher SM, Penn PE, Schindler E, et al. A comparison of smoking 
cessation treatments for persons with schizophrenia and other 
serious mental illnesses. J Psychoactive Drugs 2007;39:487–97.
 37 George TP, Vessicchio JC, Termine A, et al. A placebo controlled trial 
of bupropion for smoking cessation in schizophrenia. Biol Psychiatry 
2002:52:53–61.
 38 Tidey JW, Rohsenow DJ, Kaplan GB, et al. Effects of contingency 
management and bupropion on cigarette smoking in smokers with 
schizophrenia. Psychopharmacology 2011;217:279–87.
 39 Wing VC, Bacher I, Daskalakis ZJ, et al. A preliminary study of 
repetitive transcranial magnetic stimulation for smoking cessation in 
schizophrenia. Neuropsychopharmacology 2010;35:S163.
 40 Smith RC, Amiaz R, Si TM, et al. Varenicline effects on smoking, 
cognition, and psychiatric symptoms in schizophrenia: a double-
blind randomized trial. PLoS One 2016;11:e0143490.
 41 Tsoi DT, Porwal M, Webster AC. Interventions for smoking cessation 
and reduction in individuals with schizophrenia. Cochrane Database 
Syst Rev 2013:CD007253.
 42 Peckham E, Brabyn S, Cook L, et al. Smoking cessation in severe 
mental ill health: what works? an updated systematic review and 
meta-analysis. BMC Psychiatry 2017;17:252.
 43 Cahill K, Stevens S, Perera R, et al. Pharmacological interventions 
for smoking cessation: an overview and network meta-analysis. 
Cochrane Database Syst Rev 2013;5:CD009329.
 44 Wu P, Wilson K, Dimoulas P, et al. Effectiveness of smoking cessation 
therapies: a systematic review and meta-analysis. BMC Public Health 
2006;6:300.
 45 Anthenelli RM, Benowitz NL, West R, et al. Neuropsychiatric 
safety and efficacy of varenicline, bupropion, and nicotine patch 
in smokers with and without psychiatric disorders (EAGLES): a 
double-blind, randomised, placebo-controlled clinical trial. Lancet 
2016;387:2507–20.
 46 Muir-Cochrane E. Medical co-morbidity risk factors and barriers to 
care for people with schizophrenia. J Psychiatr Ment Health Nurs 
2006;13:447–52.
 47 Pearsall R, Hughes S, Geddes J, et al. Understanding the problems 
developing a healthy living programme in patients with serious 
mental illness: a qualitative study. BMC Psychiatry 2014;14:38.
 48 Evins AE, Mays VK, Rigotti NA, et al. A pilot trial of bupropion 
added to cognitive behavioral therapy for smoking cessation in 
schizophrenia. Nicotine & Tobacco Research 2001;3:397–403.
 49 George TP, Vessicchio JC, Termine A, et al. A placebo controlled trial 
of bupropion for smoking cessation in schizophrenia. Biol Psychiatry 
2002;52:53–61.
 50 Li J, Zhang T, Wang B, et al. An efficacy analysis of bupropion for 
smoking cessation in schizophrenia. Zhongguo Xinyao yu Linchuang 
Zazhi 2009;28:231–4.
 51 Akbarpour F, Rezaei O, Khodaie-Ardakani M-, et al. A double-
blind placebo-controlled trial of bupropion for smoking abstinence 
and cognition improvement in schizophrenia. Minerva Psichiatr 
2010;51:263–9.
 52 Bloch B, Reshef A, Cohen T, et al. Preliminary effects of bupropion 
and the promoter region (HTTLPR) serotonin transporter (SLC6A4) 
polymorphism on smoking behavior in schizophrenia. Psychiatry Res 
2010;175:38–42.
 53 Weiner E, Buchholz A, Coffay A, et al. Varenicline for smoking 
cessation in people with schizophrenia: a double blind randomized 
pilot study. Schizophr Res 2011;129:94–5.
 54 Shim J-, Jung D, Oh M, et al. Varenicline treatment for smoking 
cessation in people with schizophrenia: A randomized double-blind 
placebo-controlled trial. Schizophr Bull 2011;37:320–1.
 55 Hong E. Moderate dose varenicline treatment on neurobiological and 
cognitive biomarkers in schizophrenia smokers and non-smokers. 
Neuropsychopharmacology 2011;36:S97–S98.
 56 George TP, Ziedonis DM, Feingold A, et al. Nicotine transdermal 
patch and atypical antipsychotic medications for smoking cessation 
in schizophrenia. Am J Psychiatry 2000;157:1835–42.
 57 Weinberger AH, George TP, Perkins KA, et al. Effects of topiramate 
on smoking in patients with schizoaffective disorder, bipolar type. J 
Clin Psychopharmacol 2008;28:247–8.
 58 Szombathyne-Meszaros Z, Dimmock JA, Ploutz-Snyder R, et al. 
Oral naltrexone treatment for alcohol dependence in schizophrenia 
is not effective for smoking cessation. Alcoholism: Clinical and 
Experimental Research 2010;34:176A.
copyright.
 o
n
 D
ecem
ber 3, 2019 at University of G
lasgow. Protected by
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-027389 on 28 November 2019. Downloaded from 
